Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine
2024

Pharmacogenomic Profiling of the South Korean Population

Sample size: 396 publication Evidence: high

Author Information

Author(s): Youn Mi Seon, Ahn Se Hwan, Kim Ju Han

Primary Institution: Seoul National University College of Medicine

Hypothesis

This study aims to enhance therapeutic outcomes by providing clinicians with novel insights into the pharmacogenomic diversity of the South Korean population.

Conclusion

The study reveals significant pharmacogenetic diversity in the South Korean population, emphasizing the need for population-specific pharmacogenomic data in clinical practice.

Supporting Evidence

  • 93.43% of patients required dosage adjustments for at least one drug.
  • 48.74% of SKR individuals were classified as intermediate metabolizers for CYP2C19.
  • The high-risk *3 allele in CYP4F2 was significantly more frequent in SKR than in other East Asian populations.

Takeaway

This study looks at how people's genes affect how they respond to medicines in South Korea, helping doctors give better treatment.

Methodology

Whole genome sequencing was conducted on 396 individuals, including healthy volunteers and patients with various diseases, to identify genotype-specific drug dosing recommendations.

Limitations

The study is limited by the sample size and the need for a larger database to better represent the South Korean population.

Participant Demographics

Participants included 99 healthy volunteers, 95 patients with chronic diseases, 81 with colon cancer, 81 with breast cancer, and 40 with gastric cancer.

Statistical Information

Statistical Significance

p < 0.01

Digital Object Identifier (DOI)

10.3389/fphar.2024.1476765

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication